copaxone-injections2
29 January 2014Americas

FDA approval adds new life to Copaxone

On January 28, Teva announced that the US Food and Drug Administration (FDA) had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 November 2013   The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.

More on this story

Americas
20 November 2013   The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.

More on this story

Americas
20 November 2013   The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.